China Biologic Products Holdings, Inc.
CBPO
CBPO was delisted on the 20th of April, 2021.
138 hedge funds and large institutions have $2.08B invested in China Biologic Products Holdings, Inc. in 2016 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 53 increasing their positions, 35 reducing their positions, and 23 closing their positions.
51% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 35
39% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 23
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
5% more funds holding
Funds holding: 131 → 138 (+7)
3% less capital invested
Capital invested by funds: $2.15B → $2.08B (-$74.6M)
4% less call options, than puts
Call options by funds: $19.3M | Put options by funds: $20M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$170M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$105M |
| 3 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$39.5M |
| 4 |
Ninety One (UK)
London,
United Kingdom
|
+$21.1M |
| 5 |
YCMGA
York Capital Management Global Advisors
New York
|
+$16.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Warburg Pincus
New York
|
-$322M |
| 2 |
VAM
Visium Asset Management
New York
|
-$55.5M |
| 3 |
William Blair Investment Management
Chicago,
Illinois
|
-$24.3M |
| 4 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$20.1M |
| 5 |
Renaissance Technologies
New York
|
-$16.3M |
CBPO Hedge Fund Activity: Q2 2016 in Review
138 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q2 2016, worth a combined $2.08B — down 3.5% from $2.15B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new CBPO positions and 23 closed out — a net gain of 9 holders — while 53 added to existing stakes and 35 trimmed.
The largest buyer was Baillie Gifford & Co, opening a new position worth an estimated $170M. The largest seller was Warburg Pincus, cutting an estimated $322M.
- 138 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q2 2016, up from 131 in Q1 2016.
- Funds reported $2.08B of China Biologic Products Holdings, Inc. stock for Q2 2016, down 3.5% quarter-over-quarter.
- 32 funds opened new China Biologic Products Holdings, Inc. positions in Q2 2016 and 23 closed out, a net change of +9 holders.
- The largest China Biologic Products Holdings, Inc. buyer in Q2 2016 was Baillie Gifford & Co, an estimated $170M added.
- The largest China Biologic Products Holdings, Inc. seller in Q2 2016 was Warburg Pincus, an estimated $322M sold.
Based on aggregated 13F filings for Q2 2016.